UCB S.A. has moved closer to becoming a major player in the generalized myasthenia gravis (gMG) space with rozanolixizumab, one of the Belgian group's two late-stage candidates for the rare autoimmune disease, hitting its goals in a late-stage trial.
The Brussels-headquartered firm has revealed that the Phase III MycarinG study of rozanolixizumab met its primary endpoint, demonstrating a significant...